{"protocolSection": {"identificationModule": {"nctId": "NCT00855166", "orgStudyIdInfo": {"id": "D1690C00012"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes", "officialTitle": "A 24-week,Multi-centre,Int.,Double-blind,Rand.,Parallel-group,Plac.-Controlled,Phase III Study With a 78-week Ext.Per. to Evaluate the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone"}, "statusModule": {"statusVerifiedDate": "2013-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-02"}, "primaryCompletionDateStruct": {"date": "2010-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-03-03", "studyFirstSubmitQcDate": "2009-03-03", "studyFirstPostDateStruct": {"date": "2009-03-04", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-01-21", "resultsFirstSubmitQcDate": "2013-08-09", "resultsFirstPostDateStruct": {"date": "2013-10-14", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-08-09", "lastUpdatePostDateStruct": {"date": "2013-10-14", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}, "collaborators": [{"name": "Bristol-Myers Squibb", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "This study is being carried out to see if dapagliflozin in addition to metformin decreases body weight and if so, how it compares with metformin alone."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"], "keywords": ["Dapagliflozin", "Metformin", "Type 2 diabetes", "body weight"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 182, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "A", "type": "EXPERIMENTAL", "description": "Dapagliflozin 10 mg plus Metformin", "interventionNames": ["Drug: Dapagliflozin", "Drug: Metformin", "Drug: Sitagliptin"]}, {"label": "B", "type": "PLACEBO_COMPARATOR", "description": "Placebo plus Metformin", "interventionNames": ["Drug: Metformin", "Drug: Sitagliptin", "Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Dapagliflozin", "description": "Tablet oral 10 mg total daily dose once daily 102 weeks", "armGroupLabels": ["A"]}, {"type": "DRUG", "name": "Metformin", "description": "Tablet oral 1500 - 2500 mg total daily dose 1-3 times a day104 weeks", "armGroupLabels": ["A", "B"]}, {"type": "DRUG", "name": "Sitagliptin", "description": "Tablet oral 100 mg total daily dose once daily rescue medication", "armGroupLabels": ["A", "B"]}, {"type": "DRUG", "name": "Placebo", "description": "Matching placebo for dapagliflozin, tablet, oral, once daily, 102 weeks", "armGroupLabels": ["B"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Adjusted Mean Change in Total Body Weight", "description": "To evaluate the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin on total body weight after 24 weeks of oral administration of double-blind treatment.", "timeFrame": "Baseline to Week 24"}], "secondaryOutcomes": [{"measure": "Adjusted Mean Change in Waist Circumference", "description": "To assess the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin after 24 weeks of double-blind treatment on waist circumference.", "timeFrame": "Baseline to Week 24"}, {"measure": "Adjusted Mean Change in Body Fat Mass", "description": "To assess the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin after 24 weeks of double-blind treatment on total body fat mass measured by dual energy X-ray absorptiometry.", "timeFrame": "Baseline to Week 24"}, {"measure": "Proportion of Participants With Body Weight Decrease \u22655%", "description": "To assess the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin after 24 weeks of double-blind treatment on body weight decrease \u22655%. Least Squares Mean represents the percent of participants adjusted for body weight baseline value.", "timeFrame": "Baseline to Week 24"}], "otherOutcomes": [{"measure": "Adjusted Percent Change in Bone Mineral Density (BMD) at Lumbar Spine (L1-4)", "description": "To assess the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin after 102 weeks of double-blind treatment on Bone Mineral Density at lumbar spine (L1-4) as measured by Dual Energy X-ray Absorptiometry.", "timeFrame": "Baseline to Week 102"}, {"measure": "Adjusted Percent Change in Bone Mineral Density (BMD) at Femoral Neck", "description": "To assess the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin after 102 weeks of double-blind treatment on Bone Mineral Density at femoral neck as measured by Dual Energy X-ray Absorptiometry.", "timeFrame": "Baseline to Week 102"}, {"measure": "Adjusted Percent Change in Bone Mineral Density (BMD) at Total Hip", "description": "To assess the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin after 102 weeks of double-blind treatment on Bone Mineral Density at total hip as measured by Dual Energy X-ray Absorptiometry.", "timeFrame": "Baseline to Week 102"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Type 2 diabetes\n* Ongoing treatment with metformin on a stable dose of \u22651500 mg/day for at least 12 weeks prior to enrolment\n* Inadequate glycemic control, defined as HbA1c \u22656.5% and \u22648.5%\n* \u226530 years for males\n* \u226555 years for females\n\nExclusion Criteria:\n\n* Type 1 Diabetes\n* Body weight change \\>5% within 3 months prior to enrolment\n* Renal and liver impairment", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "30 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Jan Bolinder, MD, PhD", "affiliation": "Dept of Endocrinology, Metabolism and Diabetes Karolinska University Hospital Huddinge Karolinska Institutet 141 86 Stockholm Sweden", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Blagoevgrad", "country": "Bulgaria", "geoPoint": {"lat": 42.01667, "lon": 23.1}}, {"facility": "Research Site", "city": "Sofia", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Research Site", "city": "Beroun", "country": "Czech Republic", "geoPoint": {"lat": 49.96382, "lon": 14.072}}, {"facility": "Research Site", "city": "Brno", "country": "Czech Republic", "geoPoint": {"lat": 49.19522, "lon": 16.60796}}, {"facility": "Research Site", "city": "Praha", "country": "Czech Republic", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "Research Site", "city": "Semily", "country": "Czech Republic", "geoPoint": {"lat": 50.60191, "lon": 15.33552}}, {"facility": "Research Site", "city": "Slany", "country": "Czech Republic", "geoPoint": {"lat": 50.23046, "lon": 14.08693}}, {"facility": "Research Site", "city": "Balatonfured", "country": "Hungary", "geoPoint": {"lat": 46.96188, "lon": 17.87187}}, {"facility": "Research Site", "city": "Budapest", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Research Site", "city": "Csongrad", "country": "Hungary", "geoPoint": {"lat": 46.71332, "lon": 20.14241}}, {"facility": "Research Site", "city": "Kecskemet", "country": "Hungary", "geoPoint": {"lat": 46.90618, "lon": 19.69128}}, {"facility": "Research Site", "city": "TAT", "country": "Hungary", "geoPoint": {"lat": 47.74148, "lon": 18.64813}}, {"facility": "Research Site", "city": "Elblag", "country": "Poland", "geoPoint": {"lat": 54.1522, "lon": 19.40884}}, {"facility": "Research Site", "city": "Krakow", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Research Site", "city": "Torun", "country": "Poland", "geoPoint": {"lat": 53.01375, "lon": 18.59814}}, {"facility": "Research Site", "city": "Goteborg", "country": "Sweden", "geoPoint": {"lat": 57.70716, "lon": 11.96679}}, {"facility": "Research Site", "city": "Jarfalla", "country": "Sweden"}, {"facility": "Research Site", "city": "Lund", "country": "Sweden", "geoPoint": {"lat": 55.70584, "lon": 13.19321}}, {"facility": "Research Site", "city": "Malmo", "country": "Sweden", "geoPoint": {"lat": 55.60587, "lon": 13.00073}}, {"facility": "Research Site", "city": "Stockholm", "country": "Sweden", "geoPoint": {"lat": 59.33258, "lon": 18.0649}}, {"facility": "Research Site", "city": "Uppsala", "country": "Sweden", "geoPoint": {"lat": 59.85882, "lon": 17.63889}}]}, "referencesModule": {"references": [{"pmid": "26894924", "type": "DERIVED", "citation": "Kohan DE, Fioretto P, Johnsson K, Parikh S, Ptaszynska A, Ying L. The effect of dapagliflozin on renal function in patients with type 2 diabetes. J Nephrol. 2016 Jun;29(3):391-400. doi: 10.1007/s40620-016-0261-1. Epub 2016 Feb 19."}, {"pmid": "23906445", "type": "DERIVED", "citation": "Bolinder J, Ljunggren O, Johansson L, Wilding J, Langkilde AM, Sjostrom CD, Sugg J, Parikh S. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014 Feb;16(2):159-69. doi: 10.1111/dom.12189. Epub 2013 Aug 29."}, {"pmid": "22651373", "type": "DERIVED", "citation": "Ljunggren O, Bolinder J, Johansson L, Wilding J, Langkilde AM, Sjostrom CD, Sugg J, Parikh S. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab. 2012 Nov;14(11):990-9. doi: 10.1111/j.1463-1326.2012.01630.x. Epub 2012 Jun 29."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "During a placebo lead-in period, participants were counselled on dietary and life-style modifications. The metformin dose was adjusted to open label 1500 mg/day, 2000 mg/day or 2500 mg/day. Neither gender should exceed 60% of the total number of randomized participants.", "recruitmentDetails": "First participant enrolled: 13 Feb 2009. Last participant completed 24 week period: 03 Jun 2010. 314 participants were enrolled, 182 were randomized in 40 centers in 5 European countries. Men aged 30-75 years and women aged 55-75 years with inadequate glycemic control (HbA1c 6.5% to 8.5%), BMI of at least 25 kg/sqm and body weight \\<= 120 kg.", "groups": [{"id": "FG000", "title": "Placebo Plus Metformin", "description": "Placebo oral once daily plus metformin over 24 weeks"}, {"id": "FG001", "title": "Dapagliflozin Plus Metformin", "description": "Dapagliflozin 10 mg oral once daily plus metformin over 24 weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "91"}, {"groupId": "FG001", "comment": "Of the 91 randomized participants only 89 were included in the full analysis set.", "numSubjects": "91"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "86"}, {"groupId": "FG001", "numSubjects": "83"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "8"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Poor/non-compliance", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Administrative reasons by sponsor", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Subject no longer meets study criteria", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Full Analysis Set defined as all randomized participants (as randomized) who received at least one dose of double-blind study medication, who have a non-missing baseline value and at least one post-baseline efficacy value for at least one efficacy variable during double-blind treatment period.", "groups": [{"id": "BG000", "title": "Placebo Plus Metformin", "description": "Placebo oral once daily plus metformin over 24 weeks"}, {"id": "BG001", "title": "Dapagliflozin Plus Metformin", "description": "Dapagliflozin 10 mg oral once daily plus metformin over 24 weeks"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "91"}, {"groupId": "BG001", "value": "89"}, {"groupId": "BG002", "value": "180"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "60.8", "spread": "6.82"}, {"groupId": "BG001", "value": "60.6", "spread": "8.16"}, {"groupId": "BG002", "value": "60.7", "spread": "7.49"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "40"}, {"groupId": "BG001", "value": "40"}, {"groupId": "BG002", "value": "80"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "51"}, {"groupId": "BG001", "value": "49"}, {"groupId": "BG002", "value": "100"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "91"}, {"groupId": "BG001", "value": "89"}, {"groupId": "BG002", "value": "180"}]}]}]}, {"title": "Body Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Kilogram", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "90.91", "spread": "13.716"}, {"groupId": "BG001", "value": "92.06", "spread": "14.128"}, {"groupId": "BG002", "value": "91.48", "spread": "13.894"}]}]}]}, {"title": "Body Mass Index", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "31.68", "spread": "3.890"}, {"groupId": "BG001", "value": "32.06", "spread": "3.887"}, {"groupId": "BG002", "value": "31.87", "spread": "3.882"}]}]}]}, {"title": "Glycosylated hemoglobin A1c (HbA1c)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7.16", "spread": "0.531"}, {"groupId": "BG001", "value": "7.19", "spread": "0.443"}, {"groupId": "BG002", "value": "7.17", "spread": "0.489"}]}]}]}, {"title": "Fasting Plasma Glucose", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Milligram per deciliter", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "149.60", "spread": "25.086"}, {"groupId": "BG001", "value": "148.01", "spread": "24.650"}, {"groupId": "BG002", "value": "148.82", "spread": "24.815"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Adjusted Mean Change in Total Body Weight", "description": "To evaluate the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin on total body weight after 24 weeks of oral administration of double-blind treatment.", "populationDescription": "Full Analysis Set, participants with non-missing baseline and Week 24 (LOCF) values", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "kg", "timeFrame": "Baseline to Week 24", "groups": [{"id": "OG000", "title": "Placebo Plus Metformin", "description": "Placebo oral once daily plus metformin over 24 weeks"}, {"id": "OG001", "title": "Dapagliflozin Plus Metformin", "description": "Dapagliflozin 10 mg oral once daily plus metformin over 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "91"}, {"groupId": "OG001", "value": "89"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.88", "spread": "0.2746", "lowerLimit": "-1.43", "upperLimit": "-0.34"}, {"groupId": "OG001", "value": "-2.96", "spread": "0.2766", "lowerLimit": "-3.51", "upperLimit": "-2.41"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "H0: mean(treat) minus mean(placebo) = 0 versus the alternative HA: mean(treat) minus mean(placebo) =/= 0", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Significant at alpha=0.05 (2-sided)", "statisticalMethod": "ANCOVA", "statisticalComment": "with treatment group and stratum (gender) as effects and baseline value as covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.08", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.84", "ciUpperLimit": "-1.31", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.3885"}]}, {"type": "SECONDARY", "title": "Adjusted Mean Change in Waist Circumference", "description": "To assess the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin after 24 weeks of double-blind treatment on waist circumference.", "populationDescription": "Full Analysis Set, participants with non-missing baseline and Week 24 (LOCF) values", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "cm", "timeFrame": "Baseline to Week 24", "groups": [{"id": "OG000", "title": "Placebo Plus Metformin", "description": "Placebo oral once daily plus metformin over 24 weeks"}, {"id": "OG001", "title": "Dapagliflozin Plus Metformin", "description": "Dapagliflozin 10 mg oral once daily plus metformin over 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "91"}, {"groupId": "OG001", "value": "89"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.99", "spread": "0.4349", "lowerLimit": "-1.84", "upperLimit": "-0.13"}, {"groupId": "OG001", "value": "-2.51", "spread": "0.4388", "lowerLimit": "-3.38", "upperLimit": "-1.64"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "H0: mean(treat) minus mean(placebo) = 0 versus the alternative HA: mean(treat) minus mean(placebo) =/= 0", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0143", "pValueComment": "Significant at alpha=0.05 (2-sided). Results of key secondary endpoints are interpreted using Hochberg's method", "statisticalMethod": "ANCOVA", "statisticalComment": "with treatment group and stratum (gender) as effects and baseline value as covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.52", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.74", "ciUpperLimit": "-0.31", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.6162"}]}, {"type": "SECONDARY", "title": "Adjusted Mean Change in Body Fat Mass", "description": "To assess the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin after 24 weeks of double-blind treatment on total body fat mass measured by dual energy X-ray absorptiometry.", "populationDescription": "Full Analysis Set, participants with non-missing baseline and Week 24 (LOCF) values", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "kg", "timeFrame": "Baseline to Week 24", "groups": [{"id": "OG000", "title": "Placebo Plus Metformin", "description": "Placebo oral once daily plus metformin over 24 weeks"}, {"id": "OG001", "title": "Dapagliflozin Plus Metformin", "description": "Dapagliflozin 10 mg oral once daily plus metformin over 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "82"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.74", "spread": "0.2670", "lowerLimit": "-1.27", "upperLimit": "-0.22"}, {"groupId": "OG001", "value": "-2.22", "spread": "0.2626", "lowerLimit": "-2.74", "upperLimit": "-1.70"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "H0: mean(treat) minus mean(placebo) = 0 versus the alternative HA: mean(treat) minus mean(placebo) =/= 0", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0001", "pValueComment": "Significant at alpha=0.05 (2-sided). Results of key secondary endpoints are interpreted using Hochberg's method", "statisticalMethod": "ANCOVA", "statisticalComment": "with treatment group and stratum (gender) as effects and baseline value as covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.48", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.22", "ciUpperLimit": "-0.74", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.3731"}]}, {"type": "SECONDARY", "title": "Proportion of Participants With Body Weight Decrease \u22655%", "description": "To assess the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin after 24 weeks of double-blind treatment on body weight decrease \u22655%. Least Squares Mean represents the percent of participants adjusted for body weight baseline value.", "populationDescription": "Full Analysis Set, participants with non-missing baseline and Week 24 (LOCF) values", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage of participants", "timeFrame": "Baseline to Week 24", "groups": [{"id": "OG000", "title": "Placebo Plus Metformin", "description": "Placebo oral once daily plus metformin over 24 weeks"}, {"id": "OG001", "title": "Dapagliflozin Plus Metformin", "description": "Dapagliflozin 10 mg oral once daily plus metformin over 24 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "91"}, {"groupId": "OG001", "value": "89"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.3", "lowerLimit": "0.1", "upperLimit": "8.6"}, {"groupId": "OG001", "value": "30.6", "lowerLimit": "21.1", "upperLimit": "40.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "H0: proportion(treat) minus proportion(placebo) = 0 versus the alternative HA: proportion(treat) minus proportion(placebo) =/= 0", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Significant at alpha=0.05 (2-sided). Results of key secondary endpoints are interpreted using Hochberg's method", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Based on methodology of Zhang, Tsiatis \\& Davidian and Davidian, Tsiatis, Zhang \\& Lu, with adjustment for baseline value and stratum (gender).", "paramType": "Risk Difference (RD)", "paramValue": "26.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "15.9", "ciUpperLimit": "36.7", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "5.309"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Adjusted Percent Change in Bone Mineral Density (BMD) at Lumbar Spine (L1-4)", "description": "To assess the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin after 102 weeks of double-blind treatment on Bone Mineral Density at lumbar spine (L1-4) as measured by Dual Energy X-ray Absorptiometry.", "populationDescription": "Safety Analysis Set (all participants who received at least one dose of double-blind study medication)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent", "timeFrame": "Baseline to Week 102", "groups": [{"id": "OG000", "title": "Placebo Plus Metformin", "description": "Placebo oral once daily plus metformin over 102 weeks"}, {"id": "OG001", "title": "Dapagliflozin Plus Metformin", "description": "Dapagliflozin 10 mg oral once daily plus metformin over 102 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "68"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.47", "lowerLimit": "-0.32", "upperLimit": "1.27"}, {"groupId": "OG001", "value": "0.69", "lowerLimit": "-0.19", "upperLimit": "1.57"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "H0: mean(treat) minus mean(placebo) = 0 versus the alternative HA: mean(treat) minus mean(placebo) =/= 0", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7013", "pValueComment": "Exploratory. Model including fixed categorical effects of treatment, week, treatment-by-week interaction, gender and rescue medication as well as continuous fixed covariates of baseline measurement and baseline measurement-by-week interaction.", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Percent change in BMD from baseline to week 102 evaluated via longitudinal repeated measures analysis using direct likelihood.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.22", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.89", "ciUpperLimit": "1.34", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.5652", "estimateComment": "Natural logarithms of baseline and week 102 values were used."}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Adjusted Percent Change in Bone Mineral Density (BMD) at Femoral Neck", "description": "To assess the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin after 102 weeks of double-blind treatment on Bone Mineral Density at femoral neck as measured by Dual Energy X-ray Absorptiometry.", "populationDescription": "Safety Analysis Set (all participants who received at least one dose of double-blind study medication)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent", "timeFrame": "Baseline to Week 102", "groups": [{"id": "OG000", "title": "Placebo Plus Metformin", "description": "Placebo oral once daily plus metformin over 102 weeks"}, {"id": "OG001", "title": "Dapagliflozin Plus Metformin", "description": "Dapagliflozin 10 mg oral once daily plus metformin over 102 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "68"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.09", "lowerLimit": "-0.83", "upperLimit": "1.01"}, {"groupId": "OG001", "value": "-0.85", "lowerLimit": "-1.85", "upperLimit": "0.16"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "H0: mean(treat) minus mean(placebo) = 0 versus the alternative HA: mean(treat) minus mean(placebo) =/= 0", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1521", "pValueComment": "Exploratory. Model including fixed categorical effects of treatment, week, treatment-by-week interaction, gender and rescue medication as well as continuous fixed covariates of baseline measurement and baseline measurement-by-week interaction.", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Percent change in BMD from baseline to week 102 evaluated via longitudinal repeated measures analysis using direct likelihood.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.94", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.21", "ciUpperLimit": "0.35", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.6473", "estimateComment": "Natural logarithms of baseline and week 102 values were used."}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Adjusted Percent Change in Bone Mineral Density (BMD) at Total Hip", "description": "To assess the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin after 102 weeks of double-blind treatment on Bone Mineral Density at total hip as measured by Dual Energy X-ray Absorptiometry.", "populationDescription": "Safety Analysis Set (all participants who received at least one dose of double-blind study medication)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent", "timeFrame": "Baseline to Week 102", "groups": [{"id": "OG000", "title": "Placebo Plus Metformin", "description": "Placebo oral once daily plus metformin over 102 weeks"}, {"id": "OG001", "title": "Dapagliflozin Plus Metformin", "description": "Dapagliflozin 10 mg oral once daily plus metformin over 102 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "68"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.37", "lowerLimit": "-1.00", "upperLimit": "0.26"}, {"groupId": "OG001", "value": "-0.82", "lowerLimit": "-1.52", "upperLimit": "-0.12"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "H0: mean(treat) minus mean(placebo) = 0 versus the alternative HA: mean(treat) minus mean(placebo) =/= 0", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.3105", "pValueComment": "Exploratory. Model including fixed categorical effects of treatment, week, treatment-by-week interaction, gender and rescue medication as well as continuous fixed covariates of baseline measurement and baseline measurement-by-week interaction.", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Percent change in BMD from baseline to week 102 evaluated via longitudinal repeated measures analysis using direct likelihood.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.45", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.32", "ciUpperLimit": "0.43", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.4428", "estimateComment": "Natural logarithms of baseline and week 102 values were used."}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Non-serious / serious adverse events on or after the first day and on or prior to the last day of the 24-week double-blind treatment plus 4/30 days or up to follow-up visit if earlier, or up to and including the start date of extension period if earlier.", "description": "Participants were questioned at each study visit about the occurrence of any health problems and any examination conducted at a study visit was assessed in comparison to the status at study entry.", "eventGroups": [{"id": "EG000", "title": "Placebo Plus Metformin", "description": "Placebo oral once daily plus metformin over 24 weeks", "seriousNumAffected": 1, "seriousNumAtRisk": 91, "otherNumAffected": 9, "otherNumAtRisk": 91}, {"id": "EG001", "title": "Dapagliflozin Plus Metformin", "description": "Dapagliflozin 10 mg oral once daily plus metformin over 24 weeks", "seriousNumAffected": 6, "seriousNumAtRisk": 91, "otherNumAffected": 7, "otherNumAtRisk": 91}], "seriousEvents": [{"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 91}]}, {"term": "Vertigo", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Oesophageal varices hemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Spinal osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Transient ischemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 91}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Ulcerative keratitis", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 91}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 91}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 91}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 91}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 91}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 91}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "For participants who did not complete 24 weeks, last observation carried forward (LOCF) was used."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "If an Investigator requests permission to publish data from this study any such publication is to be agreed with AstraZeneca (AZ) in advance. The investigator agrees to provide AZ as soon as possible with drafts of proposed publications. Unless otherwise agreed, AZ shall have a period of 60 days from receipt of the proposed final manuscript to review it and may within such time require that submission for publication of the manuscript be delayed in order for AZ to file patent applications."}, "pointOfContact": {"title": "Eva Johnsson", "organization": "AstraZeneca", "email": "ClinicalTrialTransparency@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}, {"id": "D000001835", "term": "Body Weight"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M5114", "name": "Body Weight", "asFound": "Body Weight", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000529054", "term": "Dapagliflozin"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000077203", "term": "Sodium-Glucose Transporter 2 Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M348449", "name": "Dapagliflozin", "asFound": "Body weight", "relevance": "HIGH"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M1691", "name": "Sodium-Glucose Transporter 2 Inhibitors", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}